UroGen Pharma Ltd.

URGN

IL0011407140

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
13.22 ^USD	+0.08%		+3.77%	-11.87%

May. 14	Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating	MT
May. 13	Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024

UroGen Pharma Ltd. Provides Revenue Guidance for the Full Year 2022

May 10, 2022 at 09:00 am EDT

UroGen Pharma Ltd. provided revenue guidance for the full year 2022. for the year, the company expects net product revenues from Jelmyto to be in the range of $70 to $80 million.

Latest news about UroGen Pharma Ltd.

Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating	May. 14	MT
Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024	May. 13
Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $18.8M, vs. Street Est of $21.4M	May. 13	MT
UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
UroGen Pharma Ltd. Reports on New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	May. 05	CI
UroGen Pharma Ltd. Reports New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer	May. 04	CI
UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	Apr. 15	MT
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	Apr. 03	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $34 From $35, Maintains Outperform Rating	Mar. 15	MT
Transcript : UroGen Pharma Ltd., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
UroGen Pharma Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
UroGen Pharma Starts Rolling NDA Submission for Bladder Cancer Drug	Jan. 24	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $32, Maintains Outperform Rating	Jan. 24	MT
UroGen Pharma Ltd. Initiates Submission of a Rolling NDA to the FDA for UGN-102	Jan. 24	CI
Urogen Pharma Ltd. Enters into A License and Supply Agreement (The Agreement) with Medac Gesellschaft Für Klinische Spezialpräparate m.b.H	Jan. 17	CI
UroGen Pharma Ltd. Plans to Initiate Phase 3 Study in 2024	Jan. 17	CI
UroGen Signs Licensing Deal With Medac to Develop New Formulation for Urothelial Cancer; Shares Rise	Jan. 17	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $32 From $33, Maintains Outperform Rating	Nov. 15	MT
Transcript : UroGen Pharma Ltd., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (URGN) UROGEN PHARMA Reports Q3 Revenue $20.9M, vs. Street Est of $20M	Nov. 14	MT
UroGen Pharma Ltd. Reiterates Revenue Guidance for the Full Year 2023	Nov. 14	CI
North American Morning Briefing : Caution -2-	Nov. 14	DJ

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - H.C. Wainwright BioConnect Investor Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for UroGen Pharma Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.22 USD

Average target price

38 USD

Spread / Average Target

+187.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
UROGEN PHARMA LTD.	-11.87%	478M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs